A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

November 9, 2025

Primary Completion Date

July 9, 2027

Study Completion Date

July 9, 2027

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Afimkibart

Afimkibart will be administered as SC injection.

DRUG

Placebo

Placebo will be administered as SC injection.

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY